Related Experiment Video
Updated: Jul 22, 2025

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
Research and development of N,N'-diarylureas as anti-tumor agents
Xueyan Sun1, Zhizhong Xie1, Xiaoyong Lei1
1Institute of Pharmacy and Pharmacology, Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Hengyang Medical School, University of South China Hengyang Hunan 421001 China tgtzq@163.com.
Abstract:
Tumor neovascularization provides abundant nutrients for the occurrence and development of tumors, and is also an important factor in tumor invasion and metastasis, which has attracted extensive attention in anti-tumor therapy. Sorafenib is a clinically approved multi-targeted anti-tumor drug that targets vascular endothelial growth factor receptor (VEGFR) and inhibits the formation of tumor angiogenesis, thereby achieving the purpose of suppressing tumor growth. Since the approval of sorafenib, N,N'-diarylureas have received extensive attention as the key pharmacophore in its chemical structure. And a series of N,N'-diarylureas were designed and synthesized to screen a new generation of anti-tumor drug candidates through chemical modification and structural optimization. Moreover, the rational design of targeted drugs is beneficial to reduce toxic side effects and drug resistance and improve the curative effect. Here, this article reviews the research progress in the design, classification, structure-activity relationship (SAR) and biological activity of N,N'-diarylureas, in order to provide some prospective routes for the development of clinically effective anti-tumor drugs.
Insights
Researchers are exploring novel N,N'-diarylureas as anti-tumor drug candidates. These compounds, inspired by Sorafenib, target tumor angiogenesis and offer potential for improved cancer therapies.
Area of Science:
- Oncology
- Medicinal Chemistry
- Pharmacology
Background:
- Tumor neovascularization fuels tumor growth, invasion, and metastasis.
- Sorafenib, a multi-targeted drug, inhibits tumor angiogenesis by targeting vascular endothelial growth factor receptor (VEGFR).
- The N,N -diarylurea scaffold is a key pharmacophore in Sorafenib and similar anti-cancer agents.
Purpose of the Study:
- To review research on N,N -diarylureas as anti-tumor drug candidates.
- To explore their design, classification, structure-activity relationships (SAR), and biological activity.
- To identify prospective routes for developing effective anti-cancer drugs.
Main Methods:
- Literature review of N,N -diarylurea research.
- Analysis of chemical modifications and structural optimizations.
- Evaluation of biological activity and SAR data.
Main Results:
- N,N -diarylureas are recognized for their anti-angiogenic properties.
- Chemical modification and structural optimization are key to developing new drug candidates.
- Rational drug design aims to reduce side effects and overcome drug resistance.
Conclusions:
- N,N -diarylureas represent a promising class of compounds for anti-tumor drug development.
- Further research into SAR and biological activity can lead to next-generation cancer therapies.
- Targeted drug design holds potential for improved efficacy and reduced toxicity in cancer treatment.
More Related Videos
Related Concept Videos
Nucleophilic Aromatic Substitution of Aryldiazonium Salts: Aromatic SN1
In the Sandmeyer reaction, for example, the diazonio group is replaced by a chloro, bromo,...
Diazonium Group Substitution with Halogens and Cyanide: Sandmeyer and Schiemann Reactions
Diazonium Group Substitution: –OH and –H
Physical Properties of Amines
Aryldiazonium Salts to Azo Dyes: Diazo Coupling
Preparation of 1° Amines: Hofmann and Curtius Rearrangement Overview

